List of Excipients in Branded Drug ELLA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	ELLA	ulipristal acetate	50090-2835	CROSCARMELLOSE SODIUM
A-S Medication Solutions	ELLA	ulipristal acetate	50090-2835	LACTOSE MONOHYDRATE
A-S Medication Solutions	ELLA	ulipristal acetate	50090-2835	MAGNESIUM STEARATE

ELLA Excipient Strategy and Commercial Opportunities for Ulipristal Acetate

Last updated: September 24, 2026

ELLA contains 30 mg of ulipristal acetate in an immediate-release tablet. Its labeled excipients are lactose monohydrate, povidone K30, croscarmellose sodium, and magnesium stearate.[1] The strongest commercial opportunities are generic or private-label ulipristal products, improved oral formulations that reduce food sensitivity, and differentiated packs designed for rapid emergency-contraception access. The main technical constraints are low aqueous solubility, strict dose uniformity at a 30 mg strength, CYP3A4-mediated drug interactions, and the need to preserve rapid exposure after a single dose.

What excipients are used in ELLA tablets?

ELLA uses a conventional direct-compression or wet-granulation excipient system based on a disintegrant, binder, lubricant, and diluent.

Component	Function in the ELLA tablet	Commercial relevance
Ulipristal acetate, 30 mg	Active pharmaceutical ingredient	Selective progesterone receptor modulator
Lactose monohydrate	Diluent and tablet-mass carrier	Cost-effective, widely available; creates a lactose-intolerance labeling consideration
Povidone K30	Binder and granulation aid	Supports tablet mechanical strength and content uniformity
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup and immediate release
Magnesium stearate	Lubricant	Supports ejection and manufacturing efficiency

The formulation is intentionally simple. It does not use a lipid vehicle, polymeric sustained-release matrix, enteric coating, or complex amorphous solid dispersion in the marketed tablet.[1]

Why this excipient platform is technically suitable

Ulipristal acetate is administered as a single 30 mg dose. The formulation therefore needs:

• rapid tablet disintegration;
• consistent assay and content uniformity;
• adequate hardness for distribution;
• low friability;
• stability under normal storage;
• minimal excipient-driven delay in absorption.

Croscarmellose sodium is central to the immediate-release profile. Povidone K30 provides compactability and helps distribute the relatively small active dose throughout the tablet blend. Magnesium stearate must be controlled because excessive lubrication can reduce tablet wetting and delay disintegration.

Lactose is commercially efficient but is not the only viable diluent. Generic developers could evaluate microcrystalline cellulose, mannitol, dibasic calcium phosphate, spray-dried lactose, or co-processed excipients. Each substitution would require comparative dissolution, impurity, stability, and bioequivalence work.

How does ulipristal acetate affect excipient selection?

Ulipristal acetate has limited aqueous solubility and is metabolized primarily through CYP3A4. The product label identifies clinically relevant interaction concerns with strong or moderate CYP3A4 inducers and inhibitors.[1] Excipients cannot eliminate those metabolic interactions, but formulation design can influence dissolution, food effects, and exposure variability.

Solubility and dissolution

For a poorly soluble active, particle size, solid-state form, wetting, and dispersion control can be more important than simply increasing disintegrant concentration. Viable development approaches include:

1. micronized ulipristal acetate;
2. nanocrystal or nanosuspension technology;
3. amorphous solid dispersions;
4. surfactant-assisted wetting;
5. lipid-based self-emulsifying systems;
6. co-processed powder systems.

Each approach creates a different intellectual-property and regulatory profile. A basic excipient substitution may support a conventional generic application. A nanocrystal, amorphous dispersion, or lipid system may support a differentiated 505(b)(2) product, but it can also create more demanding characterization and scale-up requirements.

Food-effect management

The ELLA label reports that food can reduce peak exposure and delay the time to maximum concentration, although overall exposure is less affected.[1] A formulation that improves wetting or maintains dissolution in the presence of food could offer a commercial benefit if it produces a more consistent pharmacokinetic profile.

That benefit would need to be demonstrated in a controlled food-effect study. Faster dissolution alone would not establish clinical superiority or remove the label’s food-related administration instructions.

Dose uniformity

The active dose is only 30 mg, so blend segregation and assay variability are important manufacturing risks. Excipient selection should support:

• uniform API distribution;
• controlled particle-size distribution;
• low electrostatic charging;
• consistent bulk density;
• reproducible tablet weight;
• low lubricant sensitivity.

Ordered mixing, roller compaction, or engineered API particles may be more commercially valuable than adding a larger quantity of conventional excipient.

What formulations could compete with ELLA?

The most credible formulation opportunities fall into four categories.

Conventional immediate-release tablets

A conventional tablet using lactose or a lactose-free diluent is the lowest-risk opportunity. The product can target generic substitution, pharmacy supply contracts, institutional buyers, and private-label emergency-contraception programs.

Potential differentiators include:

• lactose-free formulation;
• smaller tablet size;
• improved packaging;
• lower manufacturing cost;
• higher tablet robustness;
• reduced moisture sensitivity;
• alternative colors or debossing;
• unit-dose blister presentation.

A conventional tablet must still demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration convenience where water is unavailable. Candidate excipients include crospovidone, croscarmellose sodium, mannitol, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The principal development risks are bitter taste, moisture sensitivity, friability, and dose uniformity. An orally disintegrating product would need to show that rapid oral disintegration does not materially alter the intended pharmacokinetic profile.

Fast-dissolving or sublingual systems

Sublingual or buccal delivery could seek faster onset or reduced gastrointestinal dependence. The commercial case is less certain because emergency contraception already relies on a single oral dose and ulipristal acetate is not labeled for sublingual administration.

A sublingual product would require new pharmacokinetic, local-tolerability, and clinical bridging work. It would be more likely to support a 505(b)(2) strategy than a routine abbreviated generic approach.

Solubility-enhanced formulations

Amorphous dispersions, nanocrystals, and lipid-based systems could target food-effect reduction or exposure consistency. These approaches may produce stronger formulation claims than a simple tablet substitution, but they carry higher CMC and scale-up costs.

Important development controls include:

• polymorph and crystallinity testing;
• particle-size monitoring;
• dissolution in biorelevant media;
• precipitation assessment;
• residual-solvent control;
• moisture uptake;
• accelerated and long-term stability;
• extractables and leachables for specialized packaging.

What patent protection covers ELLA and ulipristal acetate?

ELLA’s historical intellectual-property position has included patents directed to ulipristal acetate, related steroidal compounds, therapeutic uses, and pharmaceutical compositions. The precise current U.S. patent and Orange Book position requires a live review of FDA Orange Book and USPTO records because patent listings, delistings, terminal disclaimers, and expiration calculations can change.

The core commercial distinction is between active-ingredient claims and formulation claims:

Claim category	Typical scope	Generic-launch impact
Compound claims	Ulipristal acetate or related chemical entities	Usually the strongest early barrier, but expiration is decisive
Composition claims	Tablets, dosage forms, or excipient combinations	Can support Paragraph IV litigation if currently listed
Method-of-use claims	Emergency contraception or progesterone-receptor-modulator uses	Relevant to label carve-outs and induced-infringement risk
Manufacturing claims	Crystallization, purification, particle engineering, or solid-state control	May create supply-chain barriers even after composition expiry
Packaging claims	Blisters, moisture protection, unit-dose presentation	Usually weaker unless linked to a specific product configuration

A formulation patent is commercially valuable only if its claims cover a required product characteristic and remain enforceable. A broad claim to a tablet containing ulipristal acetate and conventional excipients can face validity and obviousness challenges. Narrow claims directed to a defined dissolution profile, solid form, particle size, or manufacturing process may be harder to design around but are also more vulnerable to non-infringement through a different process.

What is the Orange Book and Paragraph IV status of ELLA?

ELLA is an FDA-approved prescription emergency-contraception product in the United States. The FDA approved ella on August 13, 2010.[2] FDA-approved generic applicants may challenge listed patents through Paragraph IV certifications or may file a Paragraph III certification agreeing to wait for patent expiration.

The commercial questions for a potential applicant are:

1. Which patents are currently listed for the reference product?
2. Which listed patents have unexpired claims?
3. Are the patents directed to the active ingredient, formulation, method of use, or packaging?
4. Does the proposed label require a method-of-use carve-out?
5. Is pediatric exclusivity or another regulatory exclusivity period active?
6. Is the product subject to a first-filer 180-day exclusivity period?

A Paragraph IV strategy is more attractive where the remaining patents are narrow, expired, vulnerable to obviousness attacks, or avoidable through a non-infringing formulation. It is less attractive where a listed composition patent covers the only commercially practical dosage form or where the reference product has strong regulatory exclusivity protection.

No biosimilar pathway applies. Ulipristal acetate is a small-molecule drug, so competitors would use an ANDA, 505(b)(2) application, or, in limited cases, a full NDA rather than a biosimilar application.

When does ELLA lose exclusivity and face generic entry?

FDA approval in 2010 does not by itself establish the current generic-entry date. Entry depends on the interaction of:

• listed patent expiration dates;
• pediatric exclusivity;
• regulatory exclusivity;
• Paragraph IV litigation;
• 30-month stays;
• settlements;
• first-applicant exclusivity;
• approval of a substitutable generic product.

For commercial planning, the relevant timeline is:

Event	Commercial significance
August 13, 2010 FDA approval	Established ELLA as an approved U.S. reference product
Patent listing and expiration review	Determines whether ANDA applicants face active patent barriers
Paragraph IV filing	Can trigger patent litigation and a potential 30-month stay
FDA ANDA approval	Allows launch only if patent and exclusivity barriers permit
First commercial generic launch	Establishes price erosion and substitution dynamics
Multiple generic entrants	Usually increases discounting and pharmacy substitution

A generic launch could occur through several scenarios: at-risk launch after a favorable litigation result, launch after patent expiry, launch under a settlement agreement, or launch after approval with a label carve-out.

What commercial opportunities exist for ELLA excipients and formulations?

The opportunity is larger in supply-chain optimization and product differentiation than in novel excipient discovery.

Lower-cost generic supply

A developer can pursue a conventional immediate-release tablet with:

• a lower-cost diluent;
• domestic or dual-source excipients;
• reduced granulation energy;
• optimized compression speed;
• a smaller tablet;
• simplified blister packaging.

The main commercial target is price-sensitive pharmacy and wholesaler procurement.

Lactose-free positioning

Replacing lactose could support a lactose-free label and simplify procurement for customers that prefer cellulose- or mannitol-based formulations. This is a modest differentiation strategy, not a clinical superiority claim.

Improved moisture protection

Unit-dose emergency-contraception products may benefit from high-barrier blister systems using aluminum-based structures or other moisture-protective packaging. Packaging improvements can reduce stability risk and support longer shelf life, subject to real-time stability data.

Private-label and contract manufacturing

A manufacturer with validated ulipristal-acetate processing, analytical methods, and blister packaging could pursue:

• private-label pharmacy products;
• regional distributor contracts;
• international versions aligned with local regulatory pathways;
• emergency-contraception portfolios containing levonorgestrel and ulipristal acetate.

The commercial advantage comes from manufacturing reliability, regulatory support, and supply continuity rather than from excipient novelty alone.

International expansion

Ulipristal acetate emergency contraception has been marketed under names including ellaOne in Europe. Regulatory status, prescription classification, pack size, and access rules differ by jurisdiction.[3] A formulation platform that supports multiple markets can reduce development cost, but the developer must account for different excipient permissions, labeling standards, stability zones, and prescription-to-OTC classifications.

How does ELLA compare with levonorgestrel emergency contraception?

Attribute	ELLA	Levonorgestrel emergency contraception
Active ingredient	Ulipristal acetate	Levonorgestrel
Dose	30 mg once	Typically 1.5 mg once
Pharmacology	Selective progesterone receptor modulator	Progestin
Prescription status	U.S. ELLA is prescription product	Many U.S. levonorgestrel products are OTC
Excipient opportunity	Solubility, rapid disintegration, lactose-free and ODT options	Broad OTC private-label competition
Competitive barrier	Regulatory access and product-specific IP	Heavy price competition and established generic supply
Commercial positioning	Later-cycle emergency contraception and differentiated access	High-volume, low-price emergency contraception

ELLA’s commercial advantage is the distinct active ingredient and dosing profile. Its disadvantage is a more complex access and interaction profile than widely available levonorgestrel products.

How strong is the ELLA patent estate?

The patent estate should be assessed as a layered portfolio rather than as a single barrier. Compound claims provide the highest theoretical protection, while conventional excipient claims are generally easier to design around. Method-of-use claims can remain commercially relevant if the generic label includes the patented indication, but a carefully drafted carve-out may reduce infringement exposure.

The strongest remaining barriers would be claims that cover:

• a required ulipristal acetate solid form;
• a commercially necessary particle-size range;
• a defined dissolution or bioavailability profile;
• a manufacturing process that is difficult to replace;
• a listed method of use that cannot be removed from the generic label.

The weakest barriers would generally be broad claims covering ordinary tablet excipients without a demonstrated technical effect.

Key Takeaways

• ELLA is a 30 mg immediate-release ulipristal acetate tablet.
• Its labeled excipients are lactose monohydrate, povidone K30, croscarmellose sodium, and magnesium stearate.
• The most practical generic strategy is a conventional immediate-release tablet with optimized blend uniformity, disintegration, stability, and cost.
• Higher-value formulation opportunities include lactose-free tablets, orally disintegrating tablets, and solubility-enhanced systems.
• Food-effect management is a credible technical objective, but it requires clinical pharmacokinetic evidence.
• Ulipristal acetate is a small molecule, so biosimilar competition does not apply.
• Generic entry depends on current Orange Book listings, patent expiry, regulatory exclusivity, Paragraph IV litigation, and any settlement terms.
• The strongest commercial opportunities are generic supply, private-label manufacturing, barrier packaging, and international product adaptation.

FAQs

Can lactose be removed from an ELLA generic?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed diluent. The replacement must support bioequivalence, dissolution, stability, and content uniformity.

Would an orally disintegrating ELLA product qualify as a generic?

Not automatically. A product with a materially different dosage form or formulation may require a 505(b)(2) pathway unless it meets the applicable ANDA requirements for pharmaceutical equivalence and bioequivalence.

Can excipients eliminate ulipristal acetate drug interactions?

No. Excipients may influence dissolution and exposure but do not eliminate CYP3A4 induction or inhibition risks identified in the prescribing information.

Is ulipristal acetate subject to biosimilar competition?

No. Ulipristal acetate is a chemically synthesized small molecule. Competition would proceed through an ANDA, 505(b)(2) application, or NDA pathway.

What is the most defensible formulation patent strategy for ELLA?

A patent directed to a measurable technical feature, such as a defined solid form, particle-size distribution, dissolution profile, stability attribute, or manufacturing process, is generally more defensible than a broad claim covering ulipristal acetate with routine tablet excipients.

References

1. U.S. Food and Drug Administration. (2020). ELLA (ulipristal acetate) tablet: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2010, August 13). FDA approves ella for emergency contraception. FDA.

3. European Medicines Agency. (2024). ellaOne: Ulipristal acetate, EPAR product information. EMA.